Erythropoietin and progression of CKD

Kidney International

Volumn 72, Issue SUPPL. 107, 2007, Pages

  Bahlmann, F H ^a   Kielstein, J T ^a   Haller, H ^a   Fliser, D ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Anemia; Erythropoietin (EPO); Progression; Renoprotection

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; RECOMBINANT ERYTHROPOIETIN;

ACUTE DISEASE; ANEMIA; BINDING AFFINITY; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ERYTHROPOIESIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPOXIA; INTRACELLULAR SPACE; KIDNEY CIRCULATION; KIDNEY INJURY; KIDNEY ISCHEMIA; LOADING DRUG DOSE; LOW DRUG DOSE; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

EID: 35348932190     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002484     Document Type: Article

References (40)

1. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005; 6: 484-494.
2. Fliser D, De Groot K, Bahlmann FH, Haller H. Mechanisms of disease: erythropoietin - an old hormone with a new mission? Nat Clin Pract Cardiovasc Med 2006; 3: 563-572.
3. Frank SJ. Receptor dimerization in GH and erythropoietin action - it takes two to tango, but how? Endocrinology 2002; 143: 2-10.
4. Brines M, Grasso G, Fiordaliso F et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004; 101: 14907-14912.
5. Gross AW, Lodish HF. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 2006; 281: 2024-2032.
6. Sawada K, Krantz SB, Sawyer ST, Civin CI. Quantitation of specific binding of erythropoietin to human erythroid colony-forming cells. J Cell Physiol 1988; 137: 337-345.
7. Fraser JK, Lin FK, Berridge MV. Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line (HEL). Exp Hematol 1988; 16: 836-842.
8. Socolovsky M, Fallon AE, Wang S et al. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1990; 98: 181-191.
9. Datta SR, Dudek H, Tao X et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.
10. Um M, Lodish HF. Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways. J Biol Chem 2006; 281: 5648-5656.
11. Um M, Gross AW, Lodish HF. A 'classical' homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal 2007; 19: 634-645.
12. Leist M, Ghezzi P, Grasso G et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305: 239-242.
13. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999; 55: 808-820.
14. Abdelrahman M, Sharples EJ, McDonald MC et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004; 22: 63-69.
15. Bagnis C, Beaufils H, Jacquiaud C et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 2001; 16: 932-938.
16. Yang CW, Li C, Jung JY et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 2003; 17: 1754-1755.
17. Sharples EJ, Patel N, Brown P et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004; 15: 2115-2124.
18. Gong H, Wang W, Kwon TH et al. EPO and α-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int 2004; 66: 683-695.
19. Vesey DA, Cheung C, Pat B et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004; 19: 348-355.
20. Patel NS, Sharples EJ, Cuzzocrea S et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int 2004; 66: 983-989.
21. Johnson DW, Pat B, Vesey DA et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006; 69: 1806-1813.
22. Goldfarb M, Rosenberger C, Ahuva S et al. A role for erythropoietin in the attenuation of radiocontrast-induced acute renal failure in rats. Renal Fail 2006; 28: 345-350.
23. Spandou E, Tsouchnikas I, Karkavelas G et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/ reperfusion model. Nephrol Dial Transplant 2006; 21: 330-336.
24. d'Uscio LV, Smith LA, Santhanam AV et al. Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension 2007; 49: 1142-1148.
25. Santhanam AV, Smith LA, Nath KA, Katusic ZS. In vivo stimulatory effect of erythropoietin on endothelial nitric oxide synthase in cerebral arteries. Am J Physiol Heart Circ Physiol 2006; 291: H781-H786.
26. Stohlawetz PJ, Dzirlo L, Hergovich N et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000; 95: 2983-2989.
27. Haiden N, Cardona F, Schwindt J et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity. Thromb Haemost 2005; 93: 118-123.
28. Lindenblatt N, Menger MD, Klar E, Vollmar B. Darbepoetin-alpha does not promote microvascular thrombus formation in mice. role of e NOS-dependent protection through platelet and endothelial cell deactivation. Arterioscler Thromb Vasc Biol 2007; 27: 1191-1198.
29. Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol 2006; 2: 209-220.
30. Rossert J, Froissart M. Role of anemia in progression of chronic kidney disease. Semin Nephrol 2006; 26: 283-289.
31. Kuriyama S, Tomonari H, Yoshida H et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-185.
32. Tapolyai M, Kadomatsu S, Perera-Chong M. EPO treatment of pre-ESRD patients slows the rate of progression of renal decline. BMC Nephrol 2003; 4: 3.
33. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66: 753-760.
34. Drueke TB, Locatelli F, Clyne N, the CREATE Investigators et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
35. Singh AK, Szczech L, Tang KL, the CHOIR Investigators et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
36. Bahlmann FH, Song R, Boehm SM et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 100: 1006-1012.
37. Fliser D, Bahlman FH, Haller H. EPO: renoprotection beyond anemia correction. Ped Nephrol 2006; 21: 1785-1789.
38. Menne J, Park JK, Shushakova N et al. Continuous erythropoietin receptor activation affects different pathways of diabetic renal injury. J Am Soc Nephrol 2007; 18: 2046-2053.
39. Coleman TR, Westenfelder C, Togel FE et al. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci USA 2006; 103: 5965-5970.
40. Bahlmann FH, De Groot K, Spandau JM et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004; 103: 921-926.